Pluristem Announces One-for-Ten Reverse Split of its Common Shares

Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. Pluristem Therapeutics Inc. shares surged 2.5% to $1.21 in extremely heavy afternoon trade Wednesday after the company released new data from a clinical trial. The results, from a phase 2-equivalent clinical trial, focuse… Shares of Pluristem Therapeutics reverse split before market open on Thursday, July 25th 2019.

Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product and is currently conducting late stage clinical trials in several indications. PLX cell products release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company’s proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

The FDA had also approved the use of Pluristem’s PLX-PAD cells in patients who are suffering from acute respiratory distress syndrome brought on by COVID-19, but who do not qualify for the company’s clinical trial. The chart below shows how a company’s share price and consensus price target have changed over time. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Today’s financing announcement means Pluristem Therapeutics can hit the ground running to develop stem-cell based treatments for COVID-19.

Four companies unveil stock offerings

According to 7 analysts, the average rating for PLUR stock is „Buy.“ The 12-month stock price forecast is $4.08, which is an increase of 403.70% from the latest price. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Apple shares rise in late trading, adding to their regular-session advance in the wake of the company’s unveiling of its new iPhone model.

Tnuva’s strategy is to invest in companies that are synergetic to Tnuva’s core fields that will produce value while acquiring production and marketing rights. Tnuva had recently signed a know-how licensing agreement with Swiss retail giant Migros, under which Tnuva will help the Swiss company to produce dairy alternatives. Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. To be blunt, Pluristem Therapeutics is a stem cell stock that doesn’t belong in your portfolio.

Consensus Analyst Price Target

It’s received over $54 million in funding from the EU to advance its pioneering regenerative cell therapy platform, with a focus on the clinical development of the placenta-based treatment for the deadly disease. The Fund Sentiment Score finds the stocks that are being most bought by funds. It is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of institutional accumulation. The scoring model uses a combination of the total increase in disclosed owners, the changes in portfolio allocations in those owners and other metrics. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average. The chart below shows how a company’s ratings by analysts have changed over time.

The Company intends to continue bringing technology to life, creating next-generation cell-based products that improve human wellbeing, increase environmental sustainability, and advance solutions to the challenges of the future. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Analysts like Pluristem Therapeutics more than other Medical companies. The consensus rating score for Pluristem Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.64. Pluristem Therapeutics expects the $54 million financing from EIB to cover up to 50% of R&D expenses related to its COVID-19 project. The business reported only $16 million in cash on its balance sheet at the end of 2019, which means it will need additional funding — likely raised from public offerings of common stock — if the project progresses.

NASDAQ: DMTK

The company sported a market valuation of only $60 million just a few weeks ago, but has climbed to $225 million on recent announcements that it was developing treatments for COVID-19. While fellow stem-cell developer Mesoblast reported promising results today from a small clinical trial, investors cannot extrapolate that to Pluristem Therapeutics. Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond.

• The 1-10 reverse split was announced on Wednesday, July 24th 2019.
• Tnuva takes part in the establishment of advanced food tech platforms in Israel, including ‚Fresh Start,‘ an innovative food tech incubator in Northern Israel with the goal of future development of the Israeli food industry.
• Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
• The Board of Directors of the Company approved the action in accordance with Nevada law (NRS Section 78.207).
• Information is provided ‚as-is‘ and solely for informational purposes, not for trading purposes or advice, and is delayed.

BOSTON — Shares of Israel’s Pluristem Therapeutics soared 22% to $4.04 on Monday after the biotech group reported that its placenta-derived stem-cell therapy helped restore bone-marrow function in a 54-year… Four companies across a range of industries unveiled plans to offer common stock, pressuring shares after hours. Chesapeake Lodging Trust CHSP is offering 5.5 million shares as the real-estate investment trust looks to rai… Shares of Israeli biotech Pluristem Therapeutics Inc. jumped 21% in premarket trade Monday, after the company was awarded fast-track designation by the U.S. Food and Drug Administration for a treatment for Critical Limb … Haifa-based Pluristem Therapeutics Inc., a biomedical company focusing on regenerative medicine, will now be traded on the NASDAQ stock exchange.

Importantly, it also means the company can limit dilutive fundraising transactions to support research and development (R&D) efforts. But investors might still expect a public stock offering to be conducted soon. Pluristem phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Pluri’s first collaboration, based on its innovative 3D cell-based technology platform, was formed in January 2022 to produce sustainable cultured food with Israeli food giant Tnuva Group.

Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at -biotech.com or follow us on LinkedIn and Twitter. 1 brokerages have issued 1-year price targets for Pluristem Therapeutics‘ shares.

But the good news is, if China invades Taiwan, there is a way to protect yourself. In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options https://day-trading.info/ indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument. Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat’s FREE daily newsletter.

PSTI Analyst Ratings By Month

Among the companies with shares expected to actively trade in Thursday’s session are K12 Inc. PLL. K12 swung to a fiscal fourth-quarter profit as the online education provider continu… Pluristem’s shares of common stock will continue to trade on the Nasdaq Capital Market under the symbol ”PSTI” but will trade under a new CUSIP Number 72940R300.

On average, they expect the company’s stock price to reach $4.00 in the next twelve months. View analysts price targets for PSTI or view top-rated stocks among Wall Street analysts. 1 Wall Street equities research corporate bond yield curve papers and data analysts have issued „buy,“ „hold,“ and „sell“ ratings for Pluristem Therapeutics in the last year. The consensus among Wall Street equities research analysts is that investors should „buy“ PSTI shares.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Pluri stock was originally listed at a price of $3,580.00 in Jun 30, 2003. If you had invested in Pluri stock at $3,580.00, your return over the last 19 years would have been -99.98%, for an annualized return of -35.47% . Overall, this stock passed 13/33 due dilligence checks and has average fundamentals, according to our automated analysis. The Motley Fool has no position in any of the stocks mentioned.

According to analysts‘ consensus price target of $4.00, Pluristem Therapeutics has a forecasted upside of ∞ from its current price of $0.00. Pluristem Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Tnuva Group is the largest food producer in Israel, as well as the Israeli leader in the field of alternative dairy and protein products. Tnuva was founded 96 years ago and currently employs 6,000 workers in 32 sites across Israel, with annual revenues of above 2 billion dollars. Tnuva’s investment fund, ‘Tnuva NEXT’, functions as a CVC fund. Tnuva takes part in the establishment of advanced food tech platforms in Israel, including ‚Fresh Start,‘ an innovative food tech incubator in Northern Israel with the goal of future development of the Israeli food industry.